Ji Jung Hyun, Shin Seung Hwan, Park Yong Eun, Park Jihye, Park Jae Jun, Cheon Jae Hee, Kim Tae Il, Kang Sang-Bum, Park Sang Hyoung, Park Soo Jung
Department of Internal Medicine and Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Intest Res. 2024 Jul;22(3):336-350. doi: 10.5217/ir.2023.00077. Epub 2024 Mar 26.
BACKGROUND/AIMS: The impact of vaccination on inflammatory bowel disease (IBD) patients is still unknown, and no studies have assessed the changes in patient-reported outcomes (PROs) after vaccination in patients with IBD. Therefore, in this study, we investigated the impact of vaccines on the PROs of patients with IBD.
We conducted a questionnaire survey of patients with IBD who visited outpatient clinics at 4 specialized IBD clinics of referral university hospitals from April 2022 to June 2022. A total of 309 IBD patients were included in the study. Patient information was collected from a questionnaire and their medical records, including laboratory findings, were reviewed retrospectively. Risk factors associated with an increase in PROs after COVID-19 vaccination were analyzed using logistic regression analyses. In addition, we assessed whether there were differences in variables by vaccine order using the linear mixed model.
In multivariate analysis, young age ( < 40 years) and ulcerative colitis (UC) were found to be independent risk factors for aggravation of PROs in patients with IBD. In all patients, platelet count significantly increased with continued vaccination in multiple pairwise comparisons. In UC patients, PROs such as the short health scale, UC-abdominal signs and symptoms, and UC-bowel signs and symptoms were aggravated significantly with continued vaccination. There was no significant increase in the variables of patients with Crohn's disease.
Therefore, there may be a need to counsel patients with IBD younger than 40 years of age, and patients with UC before they receive COVID-19 vaccinations.
背景/目的：疫苗接种对炎症性肠病（IBD）患者的影响尚不清楚，且尚无研究评估IBD患者接种疫苗后患者报告结局（PROs）的变化。因此，在本研究中，我们调查了疫苗接种对IBD患者PROs的影响。
我们对2022年4月至2022年6月期间在4家转诊大学医院的专科IBD门诊就诊的IBD患者进行了问卷调查。共有309例IBD患者纳入研究。通过问卷调查收集患者信息，并回顾性查阅其病历，包括实验室检查结果。使用逻辑回归分析分析与COVID-19疫苗接种后PROs增加相关的危险因素。此外，我们使用线性混合模型评估按疫苗接种顺序变量是否存在差异。
在多变量分析中，发现年龄较小（<40岁）和溃疡性结肠炎（UC）是IBD患者PROs加重的独立危险因素。在所有患者中，多次两两比较显示随着持续接种疫苗血小板计数显著增加。在UC患者中，随着持续接种疫苗，简短健康量表、UC腹部体征和症状以及UC肠道体征和症状等PROs显著加重。克罗恩病患者的变量无显著增加。
因此，可能需要在40岁以下的IBD患者以及UC患者接种COVID-19疫苗前为其提供咨询。
